Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vanzacaftor QT/QTc study in healthy subjects
NCT05867147Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vanzacaftor in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Change in QT interval corrected by Fridericia's formula (QTcF). Started Apr 2023; status: completed.
02
Drugs
vanzacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05867147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867147.